SEHK:1093
SEHK:1093Pharmaceuticals

How Investors Are Reacting To CSPC Pharmaceutical Group (SEHK:1093) Advancing New Hypertension and Diabetes Treatments

CSPC Pharmaceutical Group recently reported that its aldosterone synthase inhibitor SYH2072 secured U.S. FDA and China NMPA approvals to begin clinical trials for uncontrolled and resistant hypertension, while its fixed-dose Prusogliptin and Metformin Extended-Release diabetes therapy application was accepted by China’s NMPA. These parallel advances in hypertension and type 2 diabetes programs highlight CSPC’s push into higher-value, patent-protected treatments across major chronic disease...